+

WO1997034586A3 - Dispositif et methode de traitement de maladies ophtalmiques - Google Patents

Dispositif et methode de traitement de maladies ophtalmiques Download PDF

Info

Publication number
WO1997034586A3
WO1997034586A3 PCT/US1997/004701 US9704701W WO9734586A3 WO 1997034586 A3 WO1997034586 A3 WO 1997034586A3 US 9704701 W US9704701 W US 9704701W WO 9734586 A3 WO9734586 A3 WO 9734586A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating ophthalmic
ophthalmic diseases
treating
periocularly
intraocularly
Prior art date
Application number
PCT/US1997/004701
Other languages
English (en)
Other versions
WO1997034586A2 (fr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to CA002264895A priority Critical patent/CA2264895C/fr
Priority to DE69733357T priority patent/DE69733357T2/de
Priority to US09/155,066 priority patent/US6299895B1/en
Priority to JP9533777A priority patent/JP2000507854A/ja
Priority to AU25419/97A priority patent/AU716400B2/en
Priority to AT97916936T priority patent/ATE296087T1/de
Priority to DK97916936T priority patent/DK0927024T3/da
Priority to EP97916936A priority patent/EP0927024B8/fr
Publication of WO1997034586A2 publication Critical patent/WO1997034586A2/fr
Publication of WO1997034586A3 publication Critical patent/WO1997034586A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Méthode et dispositif d'administration d'une molécule biologiquement active à l'oeil, par voie intraoculaire ou périoculaire, et méthode et dispositif de traitement de troubles ophtalmiques chez un patient.
PCT/US1997/004701 1996-03-22 1997-03-24 Dispositif et methode de traitement de maladies ophtalmiques WO1997034586A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002264895A CA2264895C (fr) 1996-03-22 1997-03-24 Dispositif et methode de traitement de maladies ophtalmiques
DE69733357T DE69733357T2 (de) 1996-03-22 1997-03-24 Apparat und verfahren zur behandlung von augenerkrankungen
US09/155,066 US6299895B1 (en) 1997-03-24 1997-03-24 Device and method for treating ophthalmic diseases
JP9533777A JP2000507854A (ja) 1996-03-22 1997-03-24 眼疾患を処置するための装置および方法
AU25419/97A AU716400B2 (en) 1996-03-22 1997-03-24 Device and method for treating ophthalmic diseases
AT97916936T ATE296087T1 (de) 1996-03-22 1997-03-24 Apparat und verfahren zur behandlung von augenerkrankungen
DK97916936T DK0927024T3 (da) 1996-03-22 1997-03-24 Indretning og fremgangsmåde til behandling af öjensygdomme
EP97916936A EP0927024B8 (fr) 1996-03-22 1997-03-24 Dispositif et methode de traitement de maladies ophtalmiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/620,982 1996-03-22
US08/620,982 US5904144A (en) 1996-03-22 1996-03-22 Method for treating ophthalmic diseases

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US08/620,982 Continuation-In-Part US5904144A (en) 1996-03-22 1996-03-22 Method for treating ophthalmic diseases
US08/620,982 Continuation US5904144A (en) 1996-03-22 1996-03-22 Method for treating ophthalmic diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/155,066 A-371-Of-International US6299895B1 (en) 1996-03-22 1997-03-24 Device and method for treating ophthalmic diseases
US09/973,325 Continuation US6436427B1 (en) 1996-03-22 2001-10-09 Device and method for treating ophthalmic diseases

Publications (2)

Publication Number Publication Date
WO1997034586A2 WO1997034586A2 (fr) 1997-09-25
WO1997034586A3 true WO1997034586A3 (fr) 1997-10-23

Family

ID=24488233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/004701 WO1997034586A2 (fr) 1996-03-22 1997-03-24 Dispositif et methode de traitement de maladies ophtalmiques

Country Status (10)

Country Link
US (1) US5904144A (fr)
EP (2) EP1574209B1 (fr)
JP (3) JP2000507854A (fr)
AT (2) ATE296087T1 (fr)
AU (1) AU716400B2 (fr)
CA (1) CA2264895C (fr)
DE (2) DE69739792D1 (fr)
DK (2) DK0927024T3 (fr)
ES (2) ES2342075T3 (fr)
WO (1) WO1997034586A2 (fr)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
IL128941A (en) 1996-09-13 2007-05-15 Advanced Medicine Res Inst An eye preparation that contains a neurotrophic factor for the treatment of a functional disease of the optic nerve
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
WO1999013868A1 (fr) * 1997-09-17 1999-03-25 Alcon Laboratories, Inc. Traitement de troubles oculaires
US7282482B2 (en) * 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
EP1154691A4 (fr) * 1999-01-05 2004-07-07 Massachusetts Eye & Ear Infirm Administration ciblee de medicament a liberation regulee vers la retine et la choroide a travers la sclerotique
US6361771B1 (en) * 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
US20070071734A1 (en) * 1999-04-06 2007-03-29 Weng Tao ARPE-19 as platform cell line for encapsulated cell-based delivery
EP1179061B1 (fr) * 1999-05-07 2006-09-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Procede de traitement de tumeurs a l'aide de composes antiangiogeniques
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
ES2231257T3 (es) * 1999-10-21 2005-05-16 Alcon Inc. Dispositivo para la administracion de farmacos.
CA2383572C (fr) 1999-10-21 2007-12-11 Alcon Universal Ltd. Administration sous-tendineuse de medicaments
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
AU780634C (en) * 2000-02-11 2006-02-23 Genvec, Inc. Gene Therapy for treating ocular-related disorders
DE60135352D1 (de) 2000-08-30 2008-09-25 Univ Johns Hopkins Vorrichtung zur intraokularen wirkstoffverabreichung
US6697668B2 (en) * 2001-01-25 2004-02-24 Iomed, Inc. Ocular iontophoretic device and method for using the same
US6546284B2 (en) * 2001-01-25 2003-04-08 Iomed, Inc. Fluid retention assembly for an iontophoretic delivery device and associated method for preparing the same
US7181287B2 (en) * 2001-02-13 2007-02-20 Second Sight Medical Products, Inc. Implantable drug delivery device
US6875165B2 (en) 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
EP1387671A1 (fr) 2001-05-03 2004-02-11 MASSACHUSETTS EYE & EAR INFIRMARY Dispositif d'administration de medicament implantable et utilisation associee
WO2002100318A2 (fr) 2001-06-12 2002-12-19 Johns Hopkins University School Of Medicine Dispositif a reservoir pour administration intra-oculaire de medicaments
US7031776B2 (en) 2001-06-29 2006-04-18 Optobionics Methods for improving damaged retinal cell function
US20050033202A1 (en) * 2001-06-29 2005-02-10 Chow Alan Y. Mechanically activated objects for treatment of degenerative retinal disease
DE10133870A1 (de) * 2001-07-12 2003-02-06 Chris P Lohmann Ophthalmisches Mittel, Verwendung von EGF zur Behandlung von Dry Eye-Syndrom und Insert zur Verabreichung von EGF am Auge
EP1409065B1 (fr) 2001-07-23 2007-01-17 Alcon, Inc. Dispositif d'administration de medicament ophtalmique
EP1385452B1 (fr) * 2001-07-23 2006-09-13 Alcon, Inc. Dispositif d'administration de medicament ophtalmique
US20040198644A1 (en) 2001-08-01 2004-10-07 Hans-Markus Bender Integrin inhibitors for the treatment of eye diseases
WO2003092665A2 (fr) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Systemes oculaires de distribution de medicament et utilisation associee
JP2006507368A (ja) * 2002-09-29 2006-03-02 サーモディックス，インコーポレイティド ステロイド含有治療剤の網膜下投与方法；脈絡膜及び網膜に薬力学作用を局在化するための方法；並びに網膜疾患の治療及び／又は予防のための関連する方法
US20060167435A1 (en) * 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
WO2004098565A2 (fr) * 2003-05-02 2004-11-18 Surmodics, Inc. Dispositif de relargage d'agent bioactif a liberation controlee
US8246974B2 (en) * 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
ATE423134T1 (de) 2003-06-10 2009-03-15 Nsgene As Verbesserte sezernierung von neublastin
MXPA05011517A (es) * 2003-07-10 2005-12-12 Alcon Inc Dispositivo para el suministro de medicamentos oftalmicos.
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
DK1677833T3 (da) 2003-10-20 2010-05-17 Nsgene As Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom
US20050136095A1 (en) * 2003-12-22 2005-06-23 Brian Levy Drug delivery device with suture ring
IL159818A0 (en) * 2004-01-12 2004-06-20 Nulens Ltd Intraocular structure
JP4602356B2 (ja) * 2004-02-12 2010-12-22 ネオビスタ、インコーポレイテッド 眼内近接照射療法のための方法および装置
US7563222B2 (en) * 2004-02-12 2009-07-21 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
JP5010464B2 (ja) 2004-03-30 2012-08-29 エヌエスジーン・アクティーゼルスカブ 成長因子、ＮｓＧ３３の治療上の使用
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
US20060110428A1 (en) 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
WO2006013462A2 (fr) * 2004-07-30 2006-02-09 Nsgene A/S Facteurs de croissance nsg28, nsg30, et nsg32
WO2006023130A2 (fr) * 2004-08-12 2006-03-02 Surmodics, Inc. Dispositif biodegradable de diffusion d'un agent bioactif a liberation lente
US8246569B1 (en) 2004-08-17 2012-08-21 California Institute Of Technology Implantable intraocular pressure drain
WO2006041805A1 (fr) * 2004-10-04 2006-04-20 Cellgate, Inc. Analogues de polyamine comme agents therapeutiques pour maladies oculaires
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
SI1848431T1 (sl) * 2005-02-09 2016-05-31 Santen Pharmaceutical Co., Ltd. Tekoče formulacije za zdravljenje bolezni ali stanj
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20060233858A1 (en) * 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
US20070077270A1 (en) * 2005-03-28 2007-04-05 Clemson University Delivery devices and methods for long-term, targeted delivery of therapeutic agents to the eye and ear
CA2603391A1 (fr) 2005-04-01 2006-10-05 Nsgene A/S Lignee cellulaire precurseur neurale immortalisee humaine
US8003124B2 (en) * 2005-04-08 2011-08-23 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
US20060258994A1 (en) * 2005-05-12 2006-11-16 Avery Robert L Implantable delivery device for administering pharmacological agents to an internal portion of a body
EP1883446B8 (fr) * 2005-05-17 2017-11-15 Gloria Therapeutics Sarl Systeme de therapie implantable pour traiter un etre vivant avec un facteur actif
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
WO2007014327A2 (fr) 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Petits composes corrigeant un mauvais repliement des proteines et utilisations de ceux-ci
WO2007059208A2 (fr) 2005-11-15 2007-05-24 Neovista Inc. Procédés et appareils pour une curiethérapie intraoculaire
MX2008006379A (es) 2005-11-29 2009-03-03 Smithkline Beecham Corp Metodo de tratamiento.
US9265814B2 (en) 2005-12-30 2016-02-23 Neurotech Usa, Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
WO2007083293A1 (fr) * 2006-01-17 2007-07-26 Nulens Ltd Distributeur de médicament intraoculaire
WO2007092620A2 (fr) 2006-02-09 2007-08-16 Macusight, Inc. Formulations stables et leurs procedes de preparation et d'utilisation
DE602007012417D1 (de) * 2006-03-14 2011-03-24 Univ Southern California Mems-Vorrichtung zur Wirkstofffreisetzung
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
CN103622778A (zh) * 2006-12-18 2014-03-12 爱尔康研究有限公司 眼用药物递送的装置与方法
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
EP2666510B1 (fr) * 2007-12-20 2017-10-18 University Of Southern California Appareil de distribution contrôlée des agents thérapeutiques
EP2727616B1 (fr) * 2008-01-03 2017-04-26 University Of Southern California Dispositifs de distribution de médicaments implantables, appareil et procédés de remplissage des dispositifs
JP2011519695A (ja) * 2008-05-08 2011-07-14 リプレニッシュ パンプス， エルエルシー 植設可能な薬物送達デバイスおよびそのデバイスを充填する装置および方法
DK2320989T3 (da) * 2008-05-08 2015-06-22 Minipumps Llc Implanterbare pumper og kanyler dertil
EP2323716B1 (fr) 2008-05-08 2015-03-04 MiniPumps, LLC Pompes d'administration de médicaments
US9849238B2 (en) 2008-05-08 2017-12-26 Minipumps, Llc Drug-delivery pump with intelligent control
JP2011522603A (ja) 2008-06-04 2011-08-04 ネオビスタ、インコーポレイテッド 放射線源ワイヤを前進させるための手持ち放射線送達システム
JP5897335B2 (ja) 2009-01-23 2016-03-30 エヌエスジーン・アクティーゼルスカブＮｓＧｅｎｅ Ａ／Ｓ 改良された細胞株及びカプセル化細胞生体送達におけるその使用
WO2010083842A2 (fr) 2009-01-23 2010-07-29 Nsgene A/S Expression de neuropeptides dans des cellules mammaliennes
US8632511B2 (en) * 2009-05-06 2014-01-21 Alcon Research, Ltd. Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
IN2012DN00352A (fr) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
MX2012002063A (es) * 2009-08-18 2012-08-01 Minipumps Llc Bomba electrolitica para la administracion de farmacos con control adaptativo.
WO2011039648A1 (fr) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Procédé d'administration et de traitement
US8177747B2 (en) * 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
WO2012041320A1 (fr) 2010-09-27 2012-04-05 Nsgene A/S Dispositif cellulaire implantable doté d'un échafaudage-support à diffusion radiale
AU2011307488B2 (en) 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
US10286146B2 (en) 2011-03-14 2019-05-14 Minipumps, Llc Implantable drug pumps and refill devices therefor
US9603997B2 (en) 2011-03-14 2017-03-28 Minipumps, Llc Implantable drug pumps and refill devices therefor
US9919099B2 (en) 2011-03-14 2018-03-20 Minipumps, Llc Implantable drug pumps and refill devices therefor
CA2838974A1 (fr) 2011-06-14 2012-12-20 Bikam Pharmaceuticals, Inc. Ligands de liaison a une opsine, compositions et procedes d'utilisation
US9474786B2 (en) 2011-09-05 2016-10-25 Nsgene A/S Treatment of allodynia
US9499464B2 (en) 2011-10-19 2016-11-22 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA2862807A1 (fr) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Ligands de liaison aux opsines, compositions et procedes d'utilisation
WO2013081642A1 (fr) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Ligands liant l'opsine, compositions et procédés d'utilisation
RU2494711C1 (ru) * 2012-05-18 2013-10-10 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ хирургического лечения прогрессирующей и осложненной миопии
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
WO2013181498A1 (fr) 2012-06-01 2013-12-05 Surmodics, Inc. Appareil et méthode de revêtement de cathéters à ballonnet
US11090468B2 (en) 2012-10-25 2021-08-17 Surmodics, Inc. Apparatus and methods for coating medical devices
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
EP3043836B1 (fr) 2013-09-11 2023-05-10 Neurotech USA, Inc. Cartouche thérapeutique à cellules encapsulées
MX383085B (es) 2014-11-10 2025-03-13 Forsight Vision4 Inc Dispositivo de entrega de fármacos expandibles y método de uso.
CA3019822A1 (fr) 2016-04-05 2017-10-12 Forsight Vision4, Inc. Dispositifs implantables d'administration de medicaments par voie oculaire
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
EP4051169A1 (fr) * 2019-11-01 2022-09-07 Neurotech USA, Inc. Système, appareils, dispositifs et procédés d'emballage d'un dispositif implantable de diffusion d'analyte

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013765A1 (fr) * 1993-11-15 1995-05-26 Oculex Pharmaceuticals, Inc. Implants oculaires biocompatibles
WO1995028166A2 (fr) * 1994-04-15 1995-10-26 Cytotherapeutics, Inc. Procede d'implantation de cellules encapsulees dans un hote

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116798A (ja) * 1974-08-01 1976-02-10 Mihairoichi Kurasunofu Mihairu Jinkosuishotai
US5266562A (en) * 1987-11-19 1993-11-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-inflammatory agents
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5382514A (en) * 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5279298A (en) * 1992-11-20 1994-01-18 The Johns Hopkins University Method and apparatus to identify and treat neovascular membranes in the eye
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5472436A (en) * 1994-07-26 1995-12-05 Fremstad; Daria A. Ocular appliance for delivering medication

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013765A1 (fr) * 1993-11-15 1995-05-26 Oculex Pharmaceuticals, Inc. Implants oculaires biocompatibles
WO1995028166A2 (fr) * 1994-04-15 1995-10-26 Cytotherapeutics, Inc. Procede d'implantation de cellules encapsulees dans un hote

Also Published As

Publication number Publication date
CA2264895A1 (fr) 1997-09-25
DK0927024T3 (da) 2005-08-29
AU2541997A (en) 1997-10-10
US5904144A (en) 1999-05-18
DE69739792D1 (de) 2010-04-15
JP2006342185A (ja) 2006-12-21
EP1574209A1 (fr) 2005-09-14
JP2010265314A (ja) 2010-11-25
JP4740077B2 (ja) 2011-08-03
EP0927024B1 (fr) 2005-05-25
JP2000507854A (ja) 2000-06-27
WO1997034586A2 (fr) 1997-09-25
ATE296087T1 (de) 2005-06-15
ES2342075T3 (es) 2010-07-01
ES2242223T3 (es) 2005-11-01
ATE459335T1 (de) 2010-03-15
AU716400B2 (en) 2000-02-24
EP0927024A2 (fr) 1999-07-07
EP1574209B1 (fr) 2010-03-03
DK1574209T3 (da) 2010-05-31
CA2264895C (fr) 2008-05-27
EP0927024B8 (fr) 2005-08-31
DE69733357D1 (de) 2005-06-30
DE69733357T2 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
WO1997034586A3 (fr) Dispositif et methode de traitement de maladies ophtalmiques
HK1046274A1 (en) Spiro Ä1-azabicycloÄ2.2.2.Üoctane-3,2'(3'h)-furoÄ2,3-bÜpyridine for use in the treatment of psychotic and intellectual impairment disorders.
AU4419897A (en) Procedure and device for corrective and therapeutic eye treatment
AU2307999A (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU9262598A (en) Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
AU2824295A (en) Controlled vacuum in ophthalmic retinal surgery
ZA975674B (en) Amphiphilic, segmented copolymer of controlled morphology and ophthalmic devices including contact lenses made therefrom.
AU3467300A (en) Method for treating glaucoma, device for realising the same and variants
AU2206699A (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1998039293A3 (fr) 13-thia prostaglandines destinees a etre utilisees dans la therapie du glaucome
EP0675120A3 (fr) Utilisation de l'ascorbyl-gamma-linolenate ou de l'ascorbyl-dihomo-gamma-linolenate pour le traitement de l'asthme, du cancer et des maladies cardiovasculaires ou inflammatoires
AU1117092A (en) Treatment of lower urinary tract disorders
ZA964762B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
ZA964761B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
WO1998026770A3 (fr) Utilisation locale d'agonistes opioïdes kappa dans le traitement de la douleur oculaire
WO1994025012A3 (fr) Medicaments pour le traitement de la migraine, de l'epilepsie et des troubles de l'alimentation
WO1997012963A3 (fr) Paf-acetylhydrolase paf et son utilisation en therapie
AU2693697A (en) Use of 2,5-dihydroxybenzenesulfonic derivatives for the manufacture of medicaments intended for the normalization of the endothelial function, for the treatment of sexual dysfunction and vascular complications of diabetes, as well as vascular disorders of endothelial origin
AU2307899A (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999053064A3 (fr) Techniques d'administration de glp-1
CA2260863A1 (fr) Traitement de troubles d'ordre psychotique
AU5659798A (en) Therapeutic composition comprising the kal protein and use of the kal protein for the treatment of retinal, renal, neuronal and neural injury
EP0968716A4 (fr) Medicaments pour le traitement des troubles circulatoires oculaires
AU6281298A (en) Use of lofexidine in the treatment of behavioral disorders
HK1054324A1 (en) The treatment of inflammatory disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD GH

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2264895

Country of ref document: CA

Ref country code: CA

Ref document number: 2264895

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997916936

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09155066

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997916936

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997916936

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载